FADS2 and urinary bladder cancer: FADS2 knockdown led to a significant increase in both GSH depletion and MDA accumulation compared to the control group (Figure 5G,H), confirming a marked increase in lipid ROS levels following FADS2 inhibition in bladder cancer cells.